<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Pak J Med Sci</journal-id><journal-id journal-id-type="iso-abbrev">Pak J Med Sci</journal-id><journal-title-group><journal-title>Pakistan Journal of Medical Sciences</journal-title></journal-title-group><issn pub-type="ppub">1682-024X</issn><issn pub-type="epub">1681-715X</issn><publisher><publisher-name>Professional Medical Publications</publisher-name><publisher-loc>Pakistan</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">29142567</article-id><article-id pub-id-type="pmc">5673736</article-id><article-id pub-id-type="publisher-id">PJMS-33-1215</article-id><article-id pub-id-type="doi">10.12669/pjms.335.13222</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>Outcomes of intravitreal bevacizumab and macular photocoagulation for treatment of diabetic macular edema in a tertiary care eye hospital, Karachi</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Jafri</surname><given-names>Adil Salim</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="corresp" rid="cor1"/></contrib><contrib contrib-type="author"><name><surname>Aziz-ur-Rehman</surname><given-names/></name><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Mirani</surname><given-names>Abdul Haleem</given-names></name><xref ref-type="aff" rid="aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Memon</surname><given-names>Saleh</given-names></name><xref ref-type="aff" rid="aff4">4</xref></contrib></contrib-group><aff id="aff1"><label>1</label>Adil Salim Jafri, Department of Ophthalmology, Al-Ibrahim Eye Hospital, Karachi, Pakistan</aff><aff id="aff2"><label>2</label>Aziz-ur-Rehman, Department of Ophthalmology, Al-Ibrahim Eye Hospital, Karachi, Pakistan</aff><aff id="aff3"><label>3</label>Abdul Haleem Mirani, Department of Ophthalmology, Al-Ibrahim Eye Hospital, Karachi, Pakistan</aff><aff id="aff4"><label>4</label>Saleh Memon, Isra Ophthalmic Research &#x00026; Development Center, Al-Ibrahim Eye Hospital, Karachi, Pakistan</aff><author-notes><corresp id="cor1">
Correspondence: Dr. Adil Salim Jafri, Isra Postgraduate Institute of Ophthalmology, Al-Ibrahim Eye Hospital, Gadap Town, Malir, Karachi, Pakistan. Email: <email xlink:href="adilsalimjafri@hotmail.com">adilsalimjafri@hotmail.com</email></corresp></author-notes><pub-date pub-type="ppub"><season>Sep-Oct</season><year>2017</year></pub-date><volume>33</volume><issue>5</issue><fpage>1215</fpage><lpage>1219</lpage><history><date date-type="received"><day>27</day><month>5</month><year>2017</year></date><date date-type="rev-recd"><day>16</day><month>8</month><year>2017</year></date><date date-type="accepted"><day>23</day><month>8</month><year>2017</year></date></history><permissions><copyright-statement>Copyright: &#x000a9; Pakistan Journal of Medical Sciences</copyright-statement><copyright-year>2017</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/3.0"><license-p><!--CREATIVE COMMONS-->This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/3.0">http://creativecommons.org/licenses/by/3.0</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><abstract><sec id="st1"><title>Objective:</title><p>To study the outcomes of intravitreal injection of Bevacizumab and laser photocoagulation in the treatment of diabetic macular edema (DME).</p></sec><sec id="st2"><title>Methods:</title><p>Seventy-two eyes of 59 patients with diabetic macular edema were divided into two groups of 41 eyes (Group-A) and 31 eyes (Group-B). Subjects in group-A were treated with three intravitreal injections of Bevacizumab (IVB), and that of group-B with macular photocoagulation. Duration of study was 9 months. Follow up pattern for both groups was1, 2, 3 and 6 months. Best Corrected Visual acuity on log MAR (BCVA) for distance as well as near in each visitwas recorded. Retinal OCT for central macular thickness (CMT) was performed on baseline. SPSS version 20.0 was used to analyze the data.</p></sec><sec id="st4"><title>Results:</title><p>Mean age of the patients was 53.76 &#x000b1; 8.82 ranging to 36-71 years. Out of 59 patients, 40 (67.8%) were male and 19 (32.2%) female. It was observed that the difference of results among both groups was not significant. Fig.2 documents visual acuity recorded as Improved; Stable and Worse.</p></sec><sec id="st5"><title>Conclusion:</title><p>The improvement in BCVA was significant at 6 months in both treatments. The final improvements in BCVA has been almost similar between both the treatment groups although it was noted that IVB group showed early improvement in BCVA at follow-ups of 1 and 3 months. A long term follow-up is required in these cases to see the effect of both these treatment strategies.</p></sec></abstract><kwd-group><title>KEYWORDS</title><kwd>Anti-VEGF</kwd><kwd>Central macular thickness</kwd><kwd>Diabetic Macular edema</kwd></kwd-group></article-meta></front><body><sec sec-type="intro" id="sec1-1"><title>INTRODUCTION</title><p>Diabetic retinopathy (DR) is the frequent microvascular complication of diabetes mellitus, affecting 7.7 million people globally<xref rid="ref1" ref-type="bibr">1</xref>,<xref rid="ref2" ref-type="bibr">2</xref> and is the common cause of blindness among people of working age in the developed world.<xref rid="ref3" ref-type="bibr">3</xref>,<xref rid="ref4" ref-type="bibr">4</xref> Chances of DR in diabetic adult&#x02019;s &#x02265;40 years old are 28.5% and risk of vision loss is 4.4% in United States.<xref rid="ref5" ref-type="bibr">5</xref> Studies originating from Pakistan have reported variable prevalence of retinopathy ranging from 15.7 to 55%.<xref rid="ref6" ref-type="bibr">6</xref>-<xref rid="ref8" ref-type="bibr">8</xref> Gaddap study reported 27.43% patients with DR and 7.51% with sight threatening diabetic retinopathy (STDR) requiring urgent intervention for vision threatening complications.<xref rid="ref9" ref-type="bibr">9</xref> Laser photocoagulation became the standard treatment for DR including DME after publication of results from the Early Treatment Diabetic Retinopathy Study in 1990.<xref rid="ref10" ref-type="bibr">10</xref>-<xref rid="ref13" ref-type="bibr">13</xref></p><p>&#x0201c;The Royal College of Ophthalmologists&#x02019; Clinical Guidelines for Diabetic Retinopathy&#x0201d; recommends laser alone if patients&#x02019; compliance is doubtful.<xref rid="ref14" ref-type="bibr">14</xref> Introduction of vascular endothelial growth factor inhibitors (anti-VEGF) have changed the scenario of the treatment especially of DME,<xref rid="ref15" ref-type="bibr">15</xref> there is marked shift towards use of anti-VEGF.<xref rid="ref16" ref-type="bibr">16</xref> Availability, cost, safety, need for repeated injection and strict monitoring and follow-up compliance of 21.2%<xref rid="ref17" ref-type="bibr">17</xref> does not make drug therapy a favorable choice for treatment of DME. Purpose of this study was to evaluate the effect of IVB and standard macular photocoagulation (MPC) in management of DME.</p></sec><sec sec-type="methods" id="sec1-2"><title>METHODS</title><p>This quasi-experimental study was conducted at Al Ibrahim Eye Hospital (AIEH) from April 2015 to December 2015. Approval of this study was obtained by ethical/research committee of Isra Postgraduate Institute of Ophthalmology. Patients with Type-2 Diabetes mellitus of either gender, &#x02265; 35 years age group, having macular edema (DME) &#x0003e; than 250&#x000b5; confirmed by retinal Optical Coherent Topography (OCT) was recruited for the study. Fundus Florescence Angiography was done to identify margins of foveal avascular zone, to rule out macular ischemia and determine the boundaries for macular grid laser application. Patients were randomly selected for both the treatment however; choice was given to the patient for opting any of the two treatments. Those who were having cardiac or cerebro-vascular problem were placed in Group-B. Sampling method carried out was &#x0201c;Non-probability, purposive&#x0201d; type.</p><p>Informed consent was taken after explaining the pros and cons of laser application and intra-vitreal injection. Seventy-two eyes of 59 patients were included in the study.13 subjects were treated bilaterally and 46 received unilateral treatment MPC was used in 31 eyes and intra-vitreal injection in 41 eyes.</p><p>After taking history, &#x0201c;Best corrected visual acuity&#x0201d; (BCVA) was taken at the time of recruitment. Detailed ocular examination was performed, a retina-trained ophthalmologist with slit lamp and dilated fundus was examined with 90D (Volk) lens FFA and retinal OCT was done using 3D OCT &#x02013; 2000 FA plus by a trained technician. Central Macular Thickness (CMT) measured as mean thickness on the 1-mm circle centered on the fovea. BCVA was taken on each follow up visit and entered into database, at one month, second month, third month and sixth month follow up visits.</p><p>Group-A received a total of three-intravitreal injections of bevacizumab (Genentech), 1.25 mg / 0.05 ml at one monthly interval. After ensuring proper sterilization; injection given through the inferior-temporal pars plana, 4 mm from the limbus in phakic and 3.5mm in pseudo-phakic eyes. All the injections were given by the principle investigator. After the injection patients were prescribed topical moxifloxacin 0.5% eye drops four times a day for one week.</p><p>Group-B received laser treatment on Pascal double frequency YAG laser. Modified grid laser photocoagulation was performed delivering 2 to 3 rows of 100-micron spots, 100 micron apart in the para-foveal region. Then, 150 to 200 micron spots were applied 200 micron apart to the remaining areas of retinal thickening and capillary non- perfusion. Focal leaks outside or within the zones of diffuse leakage were treated with 100 to 150 micron spots to achieve a mild whitening of the micro-aneurysms. No patient received Pan retinal photocoagulation.</p><p>
<list list-type="bullet"><list-item><p>Follow up pattern for both the Groups A&#x00026;B was 1 month, 2, 3 and 6 months.</p></list-item><list-item><p>BCVA was recorded on each visit.</p></list-item></list>
</p><sec id="sec2-1"><title>Main Outcome Measures</title><p>The change in best-corrected visual acuity (BCVA) at the end of 6 months considered as &#x0201c;primary outcome&#x0201d;(functional)</p></sec><sec id="sec2-2"><title>Statistical Analysis</title><p>The data was analyzed through the software SPSS version 20.0. The entire continuous variable w presented in Mean &#x000b1; Standard Deviation. The entire categorical variable was shown in frequency and Percentages. To see the significance between the groups at different visits of baseline to 1<sup>st</sup>, 2<sup>nd,</sup> 3<sup>rd</sup>&#x00026; 6<sup>th</sup> monthly intervals for BCVA. Paired sample t-test was applied. P-value &#x02264;0.05 considered statistically significant.</p></sec></sec><sec sec-type="results" id="sec1-3"><title>RESULTS</title><p>This study consisted of 59 diabetes Type-2 patients (72 eyes) Mean age of the patients was 53.76 &#x000b1; 8.82 with range of 36-71 years. Out of 59 patients, 40 (67.8%) were male and 19 (32.2%) were female. Respondents were divided in two groups. Group-A included 41 eyes who received Intravitreal Injection and Group-B had 31 eyes who received laser application.</p><p>This study of eyes with DME showed that therapy with IVB at 3 months appeared to be superior to MPC in improving visual acuity. The improvement in BCVA in both groups was statistically equal and significant at 6 months (<xref ref-type="table" rid="T1">Table-I</xref>). There was a significant difference found in mean BCVA in both groups while comparing their follow-up with significant P-values 0.001, 0.000, 0.000, 0.000 (<xref ref-type="fig" rid="F1">Fig.1</xref>). Visual acuity which was recorded in terms of improved, stable and worse is shown in <xref ref-type="fig" rid="F2">Fig.2</xref>.</p><table-wrap id="T1" position="float"><label>Table-I</label><caption><p>Mean BCVA comparison between the groups.</p></caption><table frame="hsides" rules="groups" width="100%"><thead><tr><th align="left" colspan="2" valign="top" rowspan="1"><italic>Factor (Laser =31 &#x00026; Injection = 41)</italic></th><th align="center" valign="top" rowspan="1" colspan="1"><italic>Mean</italic></th><th align="center" valign="top" rowspan="1" colspan="1"><italic>Std. Deviation</italic></th><th align="center" valign="top" rowspan="1" colspan="1"><italic>P-value</italic></th></tr></thead><tbody><tr><td align="left" rowspan="2" valign="top" colspan="1">BCVA Re Distance Pre Treatment 1st Visit Re Laser</td><td align="left" valign="top" rowspan="1" colspan="1">Laser Group</td><td align="center" valign="top" rowspan="1" colspan="1">0.7542</td><td align="center" valign="top" rowspan="1" colspan="1">0.30041</td><td align="center" rowspan="2" colspan="1">0.391</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Injection Group</td><td align="center" valign="top" rowspan="1" colspan="1">0.8137</td><td align="center" valign="top" rowspan="1" colspan="1">0.28062</td></tr><tr><td align="left" rowspan="2" valign="top" colspan="1">BCVA.R.D. 1<sup>st</sup> Month Laser</td><td align="left" valign="top" rowspan="1" colspan="1">Laser Group</td><td align="center" valign="top" rowspan="1" colspan="1">0.7458</td><td align="center" valign="top" rowspan="1" colspan="1">0.31049</td><td align="center" rowspan="2" colspan="1">0.618</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Injection Group</td><td align="center" valign="top" rowspan="1" colspan="1">0.7815</td><td align="center" valign="top" rowspan="1" colspan="1">0.29029</td></tr><tr><td align="left" rowspan="2" valign="top" colspan="1">BCVA.R.D. 2<sup>nd</sup> Month Laser</td><td align="left" valign="top" rowspan="1" colspan="1">Laser Group</td><td align="center" valign="top" rowspan="1" colspan="1">0.7029</td><td align="center" valign="top" rowspan="1" colspan="1">0.32842</td><td align="center" rowspan="2" colspan="1">0.634</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Injection Group</td><td align="center" valign="top" rowspan="1" colspan="1">0.7395</td><td align="center" valign="top" rowspan="1" colspan="1">0.31662</td></tr><tr><td align="left" rowspan="2" valign="top" colspan="1">BCVA.R.D. 3<sup>rd</sup> Month Laser</td><td align="left" valign="top" rowspan="1" colspan="1">Laser Group</td><td align="center" valign="top" rowspan="1" colspan="1">0.6500</td><td align="center" valign="top" rowspan="1" colspan="1">0.33926</td><td align="center" rowspan="2" colspan="1">0.626</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Injection Group</td><td align="center" valign="top" rowspan="1" colspan="1">0.6883</td><td align="center" valign="top" rowspan="1" colspan="1">0.31962</td></tr><tr><td align="left" rowspan="2" valign="top" colspan="1">BCVA.R.D. 6<sup>th</sup> Month Laser</td><td align="left" valign="top" rowspan="1" colspan="1">Laser Group</td><td align="center" valign="top" rowspan="1" colspan="1">0.5987</td><td align="center" valign="top" rowspan="1" colspan="1">0.36368</td><td align="center" rowspan="2" colspan="1">0.259</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Injection Group</td><td align="center" valign="top" rowspan="1" colspan="1">0.6890</td><td align="center" valign="top" rowspan="1" colspan="1">0.30877</td></tr></tbody></table></table-wrap><fig id="F1" position="float"><label>Fig.1</label><caption><p>Mean BCVA in both groups at different follow-up.</p><p>*BCVA=Best Corrected Visual Acuity</p></caption><graphic xlink:href="PJMS-33-1215-g001"/></fig><fig id="F2" position="float"><label>Fig.2</label><caption><p>Comparison of Visual Acuity.</p><p>*VA= Visual Acuity.</p></caption><graphic xlink:href="PJMS-33-1215-g002"/></fig></sec><sec sec-type="discussion" id="sec1-4"><title>DISCUSSION</title><p>Present study showed functional improvement in injection group and laser group at the end of 6 months. There were 24 eyes which were improved in injection group and 20 eyes in laser group, 12 eyes were stable and 9 eyes in laser group were stable while BCVA in 5 eyes in injection group were worsen and BCVA in 2 eyes in laser group were deteriorate (<xref ref-type="fig" rid="F2">Fig.2</xref>).</p><p>BOLT study found that intravitreal bevacizumab has a greater effect than macular laser treatment in patients with center-involving persistent CSME. At 12 months, there was a significant difference in the mean BCVA (<italic>P</italic> = 0.0006). At 2 years, the mean BCVA was also increased in the bevacizumab group compared to the macular laser therapy group (<italic>P</italic> = 0.005).</p><p>In the present study there was a significant difference found in both groups while comparing their follow-up. Subjects were with 24 eyes showed improved vision in injection group and 20 eyes in laser group, 12 eyes were stable in injection group and 9 eyes in laser group, while 5 eyes in injection group were deteriorate and 2 eyes in laser group were deteriorate (<xref ref-type="fig" rid="F2">Fig.2</xref>) From 1<sup>st</sup>, 2<sup>nd</sup>, 3<sup>rd</sup> &#x00026; 6<sup>th</sup> month BCVA improved at follow up with significant P-values 0.001, 0.000, 0.000, 0.000 (<xref ref-type="fig" rid="F1">Fig.1</xref>). Improvement in vision was seen early with IVB at 1<sup>st</sup> and 2<sup>nd</sup> month while other group started to show improvement at 3<sup>rd</sup> month. Both groups have almost statistically equal improvement of BCVA at 6 months.</p><p>Masoud Soheilian et al. reported that Intravitreal bevacizumab injection in patients with DME yielded a better visual outcome at 24 weeks compared with macular photocoagulation.<xref rid="ref26" ref-type="bibr">26</xref> Danial kook MD et al. reported that in cases with chronic diffuse ischemic diabetic macular edema (a long-term decrease of central retinal thickness) can be observed following repeated intravitreal injections of bevacizumab, he also added that &#x0201c;treatment with bevacizumab at an earlier stage of diabetic macular edema without ischemia may be associated with an even better functional outcome&#x0201d;.<xref rid="ref27" ref-type="bibr">27</xref></p><p>In this study, we also found that both IVB and MPC treatments improve VA of DME eyes, at 1<sup>st</sup> post op. month VA with IVB being significantly superior to MPC. This superiority of VA with IVB appears to wane over longer follow-up periods. At other follow-up points the significant difference was not observed in VA may be limited by effective time of bevacizumab, because its half-life in the eyes is only 9.8 days. The effectiveness of IVB on VA was greater in patients with macular edema in an early follow-up period as indicated in study by Yilmaz et al.<xref rid="ref28" ref-type="bibr">28</xref> Pharmacokinetic data suggesting a single intravitreal injection of 1.25mg bevacizumab is effective for 6-7 weeks.<xref rid="ref29" ref-type="bibr">29</xref> Limitations of IVB include regression of visual acuity within a few weeks after treatment, indicating the need for more frequent injections. Studies have reported that MPC had the ability to stabilize VA in long term and it had a significant improving effect on VA.<xref rid="ref30" ref-type="bibr">30</xref> Considering medical expenses, MPC appear to be more acceptable for the majority of DME patients, especially those in under privileged countries.</p><p>Masoud Soheilian et al. reported that Primary outcome measure was change in best-corrected VA (log MAR) at week 24. Secondary outcomes were VA changes at 6, 12, and 36 weeks, as well as CMT changes by optical coherence tomography and potential injection-related complications.<xref rid="ref26" ref-type="bibr">26</xref> In this study no significant difference was found in both the groups (<xref ref-type="table" rid="T1">Table-I</xref>).</p></sec><sec sec-type="conclusion" id="sec1-5"><title>CONCLUSION</title><p>This study of eyes with DME showed that therapy with IVB at 1 and 3 months appeared to show better improvement in best corrected vision than the laser however both modes of treatment are found to improve BCVA equally at the end of six months. Further studies over a period of 2-3 years are needed to see if the initial benefit is sustained over the time. This was a six month follow up study in order to determine stability in both vision BCVA, a long term follow up study is recommended. Sample size of this study is rather small to see the significance in difference of effect of the treatment.</p></sec></body><back><ack><title>ACKNOWLEDGEMENT</title><p>We acknowledge the support of Sight savers for conducting this research in Diabetic Eye Clinic supported by Standard Chartered bank at Al-Ibrahim Eye Hospital. Sight savers support the entire patient bearing cost of Intravitreal Injection and Laser treatment. We also acknowledge Mr. Sikander Ali Shaikh (Project Manager) for guidance and engaging with Sight savers, Dr. Anees Ahmed Khan (Diabetologist) for managing Diabetes &#x00026; Systemic disease, Ms. Khalida Parveen (Research Assistant) for data collection and entry, Ms. Seema Memon for counseling the patients and Mr. Sameer Thebo (Project Officer) for maintaining data, Muhammad Faisal Fahim (Statistician) and Muhammad Arslan (Research Officer) for making their contribution.</p></ack><fn-group><fn fn-type="COI-statement"><p><bold><italic>Declaration of Interest:</italic></bold> None.</p></fn><fn fn-type="financial-disclosure"><p><bold><italic>Grant Support &#x00026; Financial Disclosures:</italic></bold>None.</p></fn></fn-group><sec id="sec2-3"><title>Authors` Contribution</title><p><bold>ASJ and AHM:</bold> Conceived, designed, writing of manuscript and takes all the responsibility.</p><p><bold>SM and AR:</bold> Did final review for publication.</p></sec><ref-list><title>REFERENCES</title><ref id="ref1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fowler</surname><given-names>MJ</given-names></name></person-group><article-title>Microvascular and macrovascular complications of diabetes</article-title><source>Clin Diabetes</source><year>2008</year><volume>26</volume><issue>2</issue><fpage>77</fpage><lpage>82</lpage><comment>doi:10.2337/diaclin.26.2.77</comment></element-citation></ref><ref id="ref2"><label>2</label><element-citation publication-type="webpage"><collab>Prevent Blindness America</collab><source>Diabetic retinopathy. Vision Problems in the U.S</source><date-in-citation>Accessed January 28 2014</date-in-citation><comment>website. <uri xlink:type="simple" xlink:href="http://www.visionproblemsus.org/diabetic-retinopathy/diabetic-retinopathy-definition.html">http://www.visionproblemsus.org/diabetic-retinopathy/diabetic-retinopathy-definition.html</uri></comment></element-citation></ref><ref id="ref3"><label>3</label><element-citation publication-type="book"><collab>American Academy of Ophthalmology Retina Panel:Preferred practice pattern guidelines</collab><source>Diabetic retinopathy</source><year>2010</year><month>6</month><publisher-loc>San Francisco, CA</publisher-loc><publisher-name>American Academy of Ophthalmology 2008</publisher-name></element-citation></ref><ref id="ref4"><label>4</label><element-citation publication-type="journal"><source>Diabetic Retinopathy Screening Statement, National Service Framework; Dept. of Health</source><year>2008</year><month>4</month><date-in-citation>Accessed January 28 2014</date-in-citation></element-citation></ref><ref id="ref5"><label>5</label><element-citation publication-type="webpage"><source>Centers for Disease Control and Prevention, US Dept. of Health and Human Services</source><year>2014</year><date-in-citation>Accessed July 15 2016</date-in-citation><comment><uri xlink:type="simple" xlink:href="http://www.cdc.gov/diabetes/pubs/statsreport14/national-diabetes-report-web.pdf">http://www.cdc.gov/diabetes/pubs/statsreport14/national-diabetes-report-web.pdf</uri></comment></element-citation></ref><ref id="ref6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wahab</surname><given-names>S</given-names></name><name><surname>Mahmood</surname><given-names>N</given-names></name><name><surname>Sheikh</surname><given-names>Z</given-names></name><name><surname>Kazmi</surname><given-names>WH</given-names></name></person-group><article-title>Frequency of retinopathy in newly diagnosed type 2 diabetes patients</article-title><source>J Pak Med Assoc</source><year>2008</year><volume>58</volume><fpage>557</fpage><lpage>561</lpage><pub-id pub-id-type="pmid">18998309</pub-id></element-citation></ref><ref id="ref7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Niazi</surname><given-names>KM</given-names></name><name><surname>Akram</surname><given-names>A</given-names></name><name><surname>Naz</surname><given-names>AM</given-names></name><name><surname>Awan</surname><given-names>S</given-names></name></person-group><article-title>Duration of diabetes as a significant factor for retinopathy</article-title><source>Pak J Ophthalmol</source><year>2010</year><volume>26</volume><issue>4</issue><fpage>182</fpage><lpage>187</lpage></element-citation></ref><ref id="ref8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rahman</surname><given-names>S</given-names></name><name><surname>Zia</surname><given-names>I</given-names></name></person-group><article-title>Prevalence of microvascular complications among diabetic patients</article-title><source>Pak J Med Res</source><year>2004</year><volume>43</volume><issue>4</issue><fpage>163</fpage><lpage>168</lpage></element-citation></ref><ref id="ref9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mahar</surname><given-names>PS</given-names></name><name><surname>Awan</surname><given-names>MZ</given-names></name><name><surname>Manzar</surname><given-names>N</given-names></name><name><surname>Memon</surname><given-names>MS</given-names></name></person-group><article-title>Prevalence of Type-II Diabetes Mellitus and Diabetic Retinopathy:The Gaddap study</article-title><source>J Coll Physicians Surg Pak</source><year>2010</year><volume>20</volume><issue>8</issue><fpage>528</fpage><lpage>532</lpage><comment>doi:08.2010/JCPSP.528532</comment><pub-id pub-id-type="pmid">20688018</pub-id></element-citation></ref><ref id="ref10"><label>10</label><element-citation publication-type="journal"><collab>The Diabetic Retinopathy Study Research Group</collab><article-title>Photocoagulation treatment of proliferative diabetic retinopathy. Clinical application of Diabetic Retinopathy Study (DRS) findings, DRS Report Number 8</article-title><source>Ophthalmology</source><year>1981</year><volume>88</volume><issue>7</issue><fpage>583</fpage><lpage>600</lpage><pub-id pub-id-type="pmid">7196564</pub-id></element-citation></ref><ref id="ref11"><label>11</label><element-citation publication-type="journal"><collab>Early Treatment Diabetic Retinopathy Study Research Group</collab><article-title>Early photocoagulation for diabetic retinopathy. ETDRS report number 9</article-title><source>Ophthalmology</source><year>1991</year><volume>98</volume><issue>5 Suppl</issue><fpage>766</fpage><lpage>785</lpage><pub-id pub-id-type="pmid">2062512</pub-id></element-citation></ref><ref id="ref12"><label>12</label><element-citation publication-type="journal"><collab>Early Treatment Diabetic Retinopathy Study research group</collab><article-title>Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1</article-title><source>Arch Ophthalmol</source><year>1985</year><volume>103</volume><fpage>1796</fpage><lpage>806</lpage><pub-id pub-id-type="pmid">2866759</pub-id></element-citation></ref><ref id="ref13"><label>13</label><element-citation publication-type="journal"><collab>Early Treatment Diabetic Retinopathy Study design and baseline patient characteristics</collab><article-title>ETDRS report number 7</article-title><source>Ophthalmology</source><year>1991</year><volume>98</volume><fpage>741</fpage><lpage>756</lpage><pub-id pub-id-type="pmid">2062510</pub-id></element-citation></ref><ref id="ref14"><label>14</label><element-citation publication-type="journal"><article-title>The Royal College of Ophthalmologists' Clinical Guidelines for Diabetic Retinopathy:a Summary F Ghanchi</article-title><source>Eye</source><year>2013</year><volume>27</volume><issue>2</issue><fpage>285</fpage><lpage>287</lpage><pub-id pub-id-type="pmid">23306724</pub-id></element-citation></ref><ref id="ref15"><label>15</label><element-citation publication-type="journal"><source>DRCR net studies Ophthalmology. 2011;118:609-614 Retina. 2011;31:1009-1027. Ophthalmology. 2012;119:2312-2318</source><comment>doi:10.3109/08820538.2015.1114833</comment></element-citation></ref><ref id="ref16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stefanini</surname><given-names>FR</given-names></name><name><surname>Arevalo</surname><given-names>JF</given-names></name><name><surname>Maia</surname><given-names>M</given-names></name></person-group><article-title>Bevacizumab for the management of diabetic macular edema</article-title><source>World J Diab</source><year>2013</year><volume>4</volume><issue>2</issue><fpage>19</fpage><lpage>26</lpage><comment>doi:10.4239/wjd.v4.i2.19</comment></element-citation></ref><ref id="ref17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Memon</surname><given-names>S</given-names></name><name><surname>Ahsan</surname><given-names>S</given-names></name><name><surname>Alvi</surname><given-names>R</given-names></name><name><surname>Fawwad</surname><given-names>A</given-names></name><name><surname>Basit</surname><given-names>A</given-names></name><name><surname>Shera</surname><given-names>S</given-names></name><etal/></person-group><article-title>Retinal Screening Acceptance, Laser Treatment Uptake and Follow-up Response in Diabetics Requiring Laser Therapy in an Urban Diabetes Care Centre</article-title><source>J Coll Physicians Surg Pak</source><year>2015</year><volume>25</volume><issue>10</issue><fpage>743</fpage><lpage>746</lpage><pub-id pub-id-type="pmid">26454391</pub-id></element-citation></ref><ref id="ref18"><label>18</label><element-citation publication-type="journal"><article-title>Early Treatment Diabetic Retinopathy Study Research Group Photocoagulation for diabetic macular edema ETDRS number 1</article-title><source>Arch Ophthalmol</source><year>1985</year><volume>103</volume><issue>12</issue><fpage>1796</fpage><lpage>1806</lpage><pub-id pub-id-type="pmid">2866759</pub-id></element-citation></ref><ref id="ref19"><label>19</label><element-citation publication-type="journal"><article-title>Early Treatment Diabetic Retinopathy Study Research Group Early photocoagulation for diabetic retinopathy:ETDRS report number 9</article-title><source>Ophthalmology</source><year>1991</year><volume>98</volume><issue>Suppl 5</issue><fpage>766</fpage><lpage>785</lpage><pub-id pub-id-type="pmid">2062512</pub-id></element-citation></ref><ref id="ref20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shoeibi</surname><given-names>N</given-names></name><name><surname>Ahmadieh</surname><given-names>H</given-names></name><name><surname>Entezari</surname><given-names>M</given-names></name><name><surname>Yaseri</surname><given-names>M</given-names></name></person-group><article-title>Intravitreal bevacizumab with or without triamcinolone for refractory diabetic macular edema:long-term results of a clinical trial</article-title><source>J Ophthalmic Vis Res</source><year>2013</year><volume>8</volume><issue>2</issue><fpage>99</fpage><lpage>106</lpage><pub-id pub-id-type="pmid">23943683</pub-id></element-citation></ref><ref id="ref21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stefanini</surname><given-names>FR</given-names></name><name><surname>Arevalo</surname><given-names>JF</given-names></name><name><surname>Maia</surname><given-names>M</given-names></name></person-group><article-title>Bevacizumab for the management of diabetic macular edema</article-title><source>World J Diabetes</source><year>2013</year><volume>4</volume><issue>2</issue><fpage>19</fpage><lpage>26</lpage><comment>doi:10.4239/wjd.v4.i2.19</comment><pub-id pub-id-type="pmid">23593532</pub-id></element-citation></ref><ref id="ref22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thapa</surname><given-names>R</given-names></name><name><surname>Maharjan</surname><given-names>N</given-names></name><name><surname>Paudyal</surname><given-names>G</given-names></name></person-group><article-title>Intravitreal bevacizumab in macular edema secondary to branch retinal vein occlusion:12-month results</article-title><source>Clin Ophthalmol</source><year>2012</year><volume>6</volume><fpage>1057</fpage><lpage>1062</lpage><comment>doi:10.3980/j.issn.2222-3959.2014.06.26</comment><pub-id pub-id-type="pmid">22888203</pub-id></element-citation></ref><ref id="ref23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>SJ</given-names></name><name><surname>Kim</surname><given-names>ET</given-names></name><name><surname>Moon</surname><given-names>YS</given-names></name></person-group><article-title>Intravitreal bevacizumab alone versus combined with macular photocoagulation in diabetic macular edema</article-title><source>Korean J Ophthalmol</source><year>2011</year><volume>25</volume><issue>5</issue><fpage>299</fpage><lpage>304</lpage><comment>doi:10.3341/kjo.2011.25.5.299</comment><pub-id pub-id-type="pmid">21976935</pub-id></element-citation></ref><ref id="ref24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Solaiman</surname><given-names>KA</given-names></name><name><surname>Diab</surname><given-names>MM</given-names></name><name><surname>Dabour</surname><given-names>SA</given-names></name></person-group><article-title>Repeated intravitreal bevacizumab injection with and without macular grid photocoagulation for treatment of diffuse diabetic macular edema</article-title><source>Retina</source><year>2013</year><volume>33</volume><issue>8</issue><fpage>1623</fpage><lpage>1629</lpage><comment>doi:10.1097/IAE.0b013e318285c99d</comment><pub-id pub-id-type="pmid">23538584</pub-id></element-citation></ref><ref id="ref25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>XD</given-names></name><name><surname>Zhou</surname><given-names>XD</given-names></name><name><surname>Wang</surname><given-names>Z</given-names></name><name><surname>Shen</surname><given-names>HJ</given-names></name></person-group><article-title>Comparison of intravitreal bevacizumab with macular photocoagulation for treatment of diabetic macular edema:a systemic review and Meta-analysis</article-title><source>Int J Ophthalmol</source><year>2014</year><volume>7</volume><issue>6</issue><fpage>1048</fpage><lpage>1053</lpage><comment>doi:10.3980/j.issn.2222-3959.2014.06.26</comment><pub-id pub-id-type="pmid">25540764</pub-id></element-citation></ref><ref id="ref26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Soheilian</surname><given-names>M</given-names></name><name><surname>Ramezani</surname><given-names>A</given-names></name><name><surname>Obudi</surname><given-names>A</given-names></name><name><surname>Bijanzadeh</surname><given-names>B</given-names></name><name><surname>Salehipour</surname><given-names>M</given-names></name><name><surname>Yaseri</surname><given-names>M</given-names></name><etal/></person-group><article-title>Randomized Trial of Intravitreal Bevacizumab Alone or Combined with Triamcinolone versus Macular Photocoagulation in Diabetic Macular Edema</article-title><source>Am Acad Ophthalmol (Elsevier Inc.)</source><year>2009</year><volume>116</volume><issue>6</issue><fpage>1143</fpage><lpage>1150</lpage><comment>doi:10.1016/j.ophtha.2009.01.011</comment></element-citation></ref><ref id="ref27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kook</surname><given-names>D</given-names></name><name><surname>Wolf</surname><given-names>A</given-names></name><name><surname>Kreutzer</surname><given-names>T</given-names></name><name><surname>Neubauer</surname><given-names>A</given-names></name><name><surname>Strauss</surname><given-names>R</given-names></name><name><surname>Ulbig</surname><given-names>M</given-names></name><etal/></person-group><article-title>Long-Term Effect of Intravitreal Bevacizumab (Avastin) In Patients With Chronic Diffuse Diabetic Macular Edema</article-title><source>Retina</source><year>2008</year><volume>2</volume><issue>8</issue><fpage>1053</fpage><lpage>1060</lpage></element-citation></ref><ref id="ref28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yilmaz</surname><given-names>T</given-names></name><name><surname>Cordero-Coma</surname><given-names>M</given-names></name><name><surname>Gallagher</surname><given-names>MJ</given-names></name><name><surname>Teasley</surname><given-names>LA</given-names></name></person-group><article-title>Systematic review of intravitreal bevacizumab injection for treatment of primary diabetic macular oedema</article-title><source>Acta Ophthalmol</source><year>2011</year><volume>89</volume><issue>8</issue><fpage>709</fpage><lpage>717</lpage><pub-id pub-id-type="pmid">20645926</pub-id></element-citation></ref><ref id="ref29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Park</surname><given-names>YG</given-names></name><name><surname>Kim</surname><given-names>EY</given-names></name><name><surname>Roh</surname><given-names>YJ</given-names></name></person-group><article-title>Laser-Based Strategies to Treat Diabetic Macular Edema:History and New Promising Therapies</article-title><source>J Ophthalmol</source><year>2014</year><volume>2014</volume><fpage>769213</fpage><pub-id pub-id-type="pmid">25332833</pub-id></element-citation></ref><ref id="ref30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Neubauer</surname><given-names>AS</given-names></name><name><surname>Langer</surname><given-names>J</given-names></name><name><surname>Raffael</surname><given-names>Liegl</given-names></name><name><surname>Haritoglou</surname><given-names>C</given-names></name><name><surname>Wolf</surname><given-names>A</given-names></name><name><surname>Kozak</surname><given-names>L</given-names></name></person-group><article-title>Navigated macular laser decreases retreatment rate for diabetic macular edema:a comparison with conventional macular laser</article-title><source>Clin Ophthalmol</source><year>2013</year><volume>7</volume><fpage>121</fpage><lpage>128</lpage><pub-id pub-id-type="pmid">23345966</pub-id></element-citation></ref></ref-list></back></article>